

Information and Instructions for Abstract Submission

Abstract Deadline

Abstracts for the 2017 CPRIT Innovations in Cancer Prevention and Research conference are due by **September 17, 2017. No abstracts will be accepted after the advertised deadline.**

Abstract Submissions

- Only abstracts submitted through the online system will be considered.
- The submitting author must provide accurate email addresses of all co-authors and must attest that (a) all co-authors of the abstract have granted consent for the material to be submitted, and (b) that the submitting author has been granted the right by all co-authors to act on their behalf.
- Abstract Submitter will be the contact person for all correspondence about the abstract and will keep co-authors informed about its status. Only one presenting author is permissible.
- Abstract content must be based upon the best available evidence and should not promote any health care device, drug, other product, or service.
- CPRIT reserves the right to withdraw any abstract at any time.
- Abstracts will be accepted as a scientific poster and printed abstract, or as a printed abstract only; no oral presentations of abstracts will take place at the conference.
- Decision letters will be emailed to the Abstract Submitter in September 2017.
- All accepted abstracts, other than those that are withdrawn prior to publication, will be published in the conference program book and online abstract book.
- Print out and proofread the abstract preview to verify that it is correct before completing the submission process. You may make necessary edits in the abstract system until September 22, 2017.
- Submit your abstract ONLY when you are sure that your abstract is complete and in final form.

Instructions for Abstract Preparation

The online abstract submission system uses the format requested by CPRIT. Follow the steps in the system and when finished with your online submission, be sure to click the “Submit” button. The size limit for the abstract (including title, introduction, methods, results, and conclusions) is 400 words.

- No abbreviations may be used in the title (except for standard abbreviations like DNA).
- Do not use capital letters in the title except for words that are always capitalized. Do not capitalize every word.
- The Presenting Author is the first author on the abstract.
- Degrees of authors may be listed, but will not be included in publication.
- The abstract must be in English.
- Abstracts may NOT include tables, charts, or figures.
- The body of the abstract should consist of 4 sections: Introduction, Methods, Results, and Conclusions. Each section is a required field. The full abstract is limited to 400 words.
- Abbreviations may be used if standard (e.g., DNA) or if spelled out and defined at the first use.

Subject Categories for Abstract

ACADEMIC RESEARCH CATEGORIES

- Cancer Biology
- Etiology/Early Detection/Diagnosis
- Prevention/Cancer Control/Survivorship
- Scientific Model Systems
- Treatments and Therapeutics

PRODUCT DEVELOPMENT RESEARCH CATEGORIES

- Detection and Diagnostics
- Treatments and Therapeutics

PREVENTION CATEGORIES

- Primary Prevention
- Early Detection and Screening
- Survivorship

FDA Disclosure

- If a device or drug requiring FDA approval is included in the abstract/poster content, the content must include the FDA clearance status of the medical device/pharmaceutical for the uses described or discussed. Off-label uses of a device or pharmaceutical may be described so long as the lack of FDA clearance for such uses is also disclosed.
- Posters exhibiting a Class III device or pharmaceutical require signage indicating the FDA status of the product.
- Categories: Approved, Not Approved, Cleared, or Not Applicable. CPRIT will accept abstracts for all categories.

Submission Agreement

- The submitter must agree to the terms and conditions of the submission agreement before submitting an abstract.

Abstract Revisions and Withdrawal

- To withdraw an abstract, please contact abstracts@cprit.texas.gov.
- The deadline for abstract content and author revisions is September 22, 2017. You may log on to the abstract submission site to make any necessary changes. Abstract content or author revision requests received after this date will not be made.

Information and Instructions for Poster Sessions

- Posters must be designed to fit the poster board; posters will be displayed in landscape format on boards 42 inches high by 84 inches wide. The poster title and author block should be displayed across the top of the poster. This allows meeting participants to find posters easily.
- Posters must be substantively identical to that described in the abstract. The title, authorship, and scientific content must match the abstract.
- Posters have been assigned to Poster Session A or Poster Session B. Poster Session A is scheduled for Monday, November 13 from 3:00 pm to 4:45 pm. Poster Session B is scheduled for Tuesday, November 14 from 10:00 am to 11:30 am.
- Scientific posters have been assigned designated poster boards and will be grouped by program and category within each program. Each scientific poster must correspond with the assigned poster board number. This number is not the same as the submission ID number.
- Posters based on a CPRIT grant should display the CPRIT logo; the logo file is on the CPRIT website [here](#). The previous CPRIT logo should NOT be used.
- Scientific posters may be set up on Sunday, November 12 from 3:00 pm to 5:00 pm and on Monday, November 13, from 7:30 am to 12:00 pm. CPRIT will provide push pins and storage for poster containers.
- Posters should be set up no later than Monday, November 13 at 12:00 pm and should remain on display until 12:00 pm on Tuesday, November 14, after which they may be taken down. CPRIT is not responsible for any posters remaining after the conference closes. CPRIT will not ship posters back to authors.
- At least one of the authors should stand with their poster for the entirety of the assigned session to answer any questions. If you are assigned to Session A, CPRIT asks that you do NOT remove your poster until the end of Session B so that all meeting participants have the opportunity to see all posters.